Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

MBCProject_0065_T1_RNA

— · C

63faa614-1a50-574c-8be0-3c71afc3ee4e

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
C
subtype
C

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.610
  • ANGIOGENESIS+0.560
  • ALLOGRAFT_REJECTION+0.480
  • INFLAMMATORY_RESPONSE+0.450
  • NOTCH_SIGNALING+0.420
  • IL6_JAK_STAT3_SIGNALING+0.410
  • INTERFERON_GAMMA_RESPONSE+0.410
  • COAGULATION+0.400
  • COMPLEMENT+0.400
  • TNFA_SIGNALING_VIA_NFKB+0.350

Top 10 suppressed

  • MYC_TARGETS_V2-0.370
  • DNA_REPAIR-0.230
  • OXIDATIVE_PHOSPHORYLATION-0.210
  • ESTROGEN_RESPONSE_EARLY-0.190
  • ESTROGEN_RESPONSE_LATE-0.130
  • HEME_METABOLISM-0.130
  • E2F_TARGETS-0.090
  • PEROXISOME-0.070
  • MYC_TARGETS_V1-0.060
  • P53_PATHWAY-0.060

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

9 twins match this tumor's tissue · 1 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1MBCProject_0698_T1_RNA
breast-umap@18
—A0.915
2MDT-AP-2029
medullo-epn-umap@date-based
MedMedulloblastoma0.874
3TCGA-GV-A3QG-01A-11R-A220-07
bladder-landscape@3
——0.869
4TCGA-CV-7433-01A-11R-2132-07
head-neck@1
——0.865
5TCGA-BH-A0BR-01A-21R-A115-07
breast-umap@18
—C0.865
6SRR10900576
melanoma-umap@29
——0.865
7MBCProject_0022_T1_RNA
breast-umap@18
—D0.860
8SRR1313138
breast-umap@18
—D0.859
9TCGA-AN-A0XW-01A-11R-A109-07
breast-umap@18
—C0.858
10R303
bladder-landscape@3
——0.857

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 38 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
EPITHELIAL_MESENCHYMAL_TRANSITION0.610Inavolisib— uncovered
ANGIOGENESIS0.560Remibrutinib— uncovered
ALLOGRAFT_REJECTION0.480Idelalisib— uncovered
INFLAMMATORY_RESPONSE0.450Idelalisib— uncovered
NOTCH_SIGNALING0.420Inavolisib— uncovered
IL6_JAK_STAT3_SIGNALING0.410Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.410Idelalisib— uncovered
COAGULATION0.400Binimetinib— uncovered
COMPLEMENT0.400Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.350Inavolisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.340Remibrutinib— uncovered
HEDGEHOG_SIGNALING0.320Inavolisib— uncovered
MTORC1_SIGNALING0.320Inavolisib— uncovered
IL2_STAT5_SIGNALING0.310Idelalisib— uncovered
KRAS_SIGNALING_UP0.310Inavolisib— uncovered
INTERFERON_ALPHA_RESPONSE0.290Inavolisib— uncovered
MYOGENESIS0.280Inavolisib— uncovered
TGF_BETA_SIGNALING0.270Inavolisib— uncovered
APOPTOSIS0.250Idelalisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.250Inavolisib— uncovered